UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 795.5	$ 678.3
Short-term investments	56.2	6.6
Accounts receivable, net	325.5	362.2
Inventories	625.5	577.2
Other current assets	187.3	172.0
Total current assets	1,990.0	1,796.3
Property, plant and equipment, net	318.6	306.1
Goodwill	290.0	293.0
Operating lease assets	62.3	65.6
Intangibles, net and other long-term assets	301.0	310.5
Total assets	2,961.9	2,771.5
Current liabilities:
Current portion of long-term debt	95.8	0.5
Accounts payable	127.0	118.4
Customer advances	141.8	137.9
Other current liabilities	401.2	388.8
Total current liabilities	765.8	645.6
Long-term debt	914.8	812.8
Operating lease liabilities	44.3	47.0
Other long-term liabilities	312.4	327.9
Commitments and contingencies (Note 13)
Redeemable noncontrolling interest		21.1
Shareholders' equity:
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding
Common stock, $0.01 par value 260,000,000 shares authorized, 173,573,073 and 173,502,375 shares issued and 154,226,496 and 154,155,798 shares outstanding at March 31, 2020 and December 31, 2019, respectively	1.7	1.7
Treasury stock, at cost, 19,346,577 shares at March 31, 2020 and December 31, 2019	(543.8)	(543.8)
Accumulated other comprehensive income	(23.3)	(25.5)
Other shareholders' equity	1,481.0	1,474.4
Total shareholders' equity attributable to Bruker Corporation	915.6	906.8
Noncontrolling interest in consolidated subsidiaries	9.0	10.3
Total shareholders' equity	924.6	917.1
Total liabilities and shareholders' equity	$ 2,961.9	$ 2,771.5